Exelixis is an oncology company that develops and commercializes targeted cancer therapies, generating revenues primarily from two marketed formulations of cabozantinib—CABOMETYX and COMETRIQ—approved for treatment of advanced renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, and neuroendocrine tumors, along with cobimetinib for melanoma and esaxerenone for hypertension. The company sells directly to oncologists and healthcare providers in the United States through an integrated commercial team and digital marketing, while leveraging international partnership agreements with Ipsen and other collaborators to distribute products outside the U.S. and to expand clinical programs. Exelixis advances a pipeline of small-molecule kinase inhibitors and biotherapeutics including zanzalintinib and novel antibody-drug conjugates through partnerships with major pharmaceutical firms and research institutions, while outsourcing manufacturing to contract partners and supporting patient access through its assistance programs.